Scorpion’s new facility is designed for the development and manufacturing of clinical and commercial-scale biologic drugs.
Scorpion Biological Services, a contract development and manufacturing organization focused on the development of biologic drugs, recently hosted the grand opening of its new San Antonio, TX facility. The new facility is designed for the development and manufacturing of clinical and commercial-scale biologics.
“After more than 18 months of tireless work, preparation, dedication from our excellent team, and support from the San Antonio community, we have finally arrived at this moment where we can cut the ribbon, open our doors, and get to work,” said David Halverson, president of Scorpion, in an Oct. 25, 2022 company press release. “This facility will be at the forefront of American biomanufacturing, developing clinical and commercial-scale large molecules, so we can help our clients bring their biologic innovations from the lab to the clinic and to the patients that need them.”
“This is an extraordinarily exciting milestone for our company,” said Jeff Wolf, founder and chairman, Scorpion, in the release. “Today, we checked off a major milestone with the grand opening of Scorpion’s San Antonio manufacturing facility. It is years in the making, and we are thrilled to get the real work started, right here, right now.”
Source: Scorpion Biological Services
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.